Key facts
- ANEXT (China)’s last known valuation is $83.2M (Aug 2024).
- It has raised $14.0M; the latest was Later Stage VC in Dec 2024.
- Notable investors include Huayi Capital, The Oriental Beauty Valley, Huilian Investment, Shanghai Huamin Investment.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for ANEXT (China)
- ·The full record, as it builds
Funding rounds
No funding rounds for ANEXT (China) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ANEXT (China)
Developer of new drugs and delivery methods designed for anti-aging and reversing aging purposes. The company can realize the development of new drugs and change the conventional drug delivery methods to obtain highly optimized cell therapy methods through the newly discovered "naturally domesticated" biomolecule drug carriers Exosomes and engineering transformation, providing customers with reliable and creative products.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2013
- Employees
- 2
- Website
- anextcell.com/
- Ownership
- Privately Held (backing)
ANEXT (China) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ANEXT (China) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ANEXT (China) in its N-PORT filings yet. We sweep new filings monthly.